Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 3/20 | 0.48 |
| ▸ | BLM | P54132 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | CASP1 | P29466 | 2/20 | 0.48 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 2/20 | 0.48 |
| ▸ | CASP7 | P55210 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14125002 | 0.80 | NOTUM (0.56) | ALDH1A1NPC1RAB9AKDM4EMEN1 | |
| SCHEMBL1799678 | 0.77 | ALDH1A1 (0.63) | ALDH1A1NPC1RAB9AHSD17B10KDM4E | |
| SCHEMBL11974601 | 0.67 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9AHSD17B10KDM4E | |
| SCHEMBL11974594 | 0.67 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9AHSD17B10KDM4E | |
| SCHEMBL17951449 | 0.67 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9AHSD17B10KDM4E | |
| SCHEMBL11974593 | 0.67 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9AHSD17B10KDM4E | |
| SCHEMBL11974592 | 0.67 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9AHSD17B10KDM4E | |
| SCHEMBL9768763 | 0.67 | NOTUM (0.77) | ALDH1A1NPC1RAB9AKDM4EPOLB | |
| SCHEMBL11974595 | 0.67 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9AHSD17B10KDM4E | |
| SCHEMBL11974596 | 0.67 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9AHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | claimed |
| EP-0486782-A1 | Improved process for the synthesis of alpha-((dialkylamino)substituted-methylene)-beta-oxo-(substituted) propanenitriles | AMERICAN CYANAMID COMPANY (US) | 1992-05-27 | — | — | EP | claimed |
| US-5103015-A | 5-(substituted)isoxazole compounds | AMERICAN CYANAMID COMPANY (US) | 1992-04-07 | — | — | US | claimed |
| US-12404270-B2 | Quinazoline derivatives as LPA receptor 2 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-09-02 | — | — | US | disclosed |
| WO-2024045890-A1 | PREPARATION METHOD FOR DENDRITIC CELL PROGENITORS AND CULTURE MEDIUM THEREOF | 浙江吉量科技有限公司 | 2024-03-07 | — | — | WO | disclosed |
| US-20230063121-A1 | QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-03-02 | — | — | US | disclosed |
| CN-115087656-A | ATF6 modulators and uses thereof | 普拉西斯生物技术有限责任公司 | 2022-09-20 | — | — | CN | disclosed |
| US-9340517-B2 | Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor | MIMETICA PTY LTD (AU) | 2016-05-17 | — | — | US | disclosed |
| US-20130225563-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MIMETICA PTY LTD (AU) | 2013-08-29 | — | — | US | disclosed |
| US-8377925-B2 | Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor | MIMETICA PTY LTD (AU) | 2013-02-19 | — | — | US | disclosed |
| US-8343958-B2 | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists | MIMETICA PTY LTD (AU) | 2013-01-01 | — | — | US | disclosed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20090221558-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | Marp Therapeutics Pty Ltd (AU) | 2009-09-03 | — | — | US | disclosed |
| US-20090221557-A1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | Marp Therapeutics Pty Ltd (AU) | 2009-09-03 | — | — | US | disclosed |
| US-5103015-A | 5-(substituted)isoxazole compounds | AMERICAN CYANAMID COMPANY (US) | 1992-04-07 | — | — | US | disclosed |
| US-5059709-A | Reacting substituted isoxazole with dialkylamide dimethylacetal; anxiolytic agents | AMERICAN CYANAMID COMPANY (US) | 1991-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404270-B2 | Quinazoline derivatives as LPA receptor 2 inhibitors | LPAR2, LPAR1, LPAR5 | ALDH1A1 2204/4885NPC1 571/4885RAB9A 700/4885 |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | ALDH1A1 2806/4885NPC1 3444/4885RAB9A 1714/4885 |
| US-20090221558-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MC5R, MC1R, MC3R | ALDH1A1 2828/4885NPC1 2059/4885RAB9A 3118/4885 |
| US-20130225563-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MC5R, MC1R, MC3R | ALDH1A1 2828/4885NPC1 2059/4885RAB9A 3118/4885 |
| US-20090221557-A1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | MC5R, MC1R, MC3R | ALDH1A1 2040/4885NPC1 1978/4885RAB9A 2874/4885 |
| US-20230063121-A1 | QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | LPAR2, LPAR1, LPAR5 | ALDH1A1 2204/4885NPC1 571/4885RAB9A 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.